Skip to main content
Premium Trial:

Request an Annual Quote

GenOdyssee Appoints Former Chiron Executive as VP for Preclinical and Clinical Affairs

NEW YORK, June 26 – French functional genomics company GenOdyssee has appointed Jean Maral, a former Chiron Biopharmaceuticals executive, to the position of vice president and senior director of preclinical and clinical affairs, the company said Tuesday. 

In addition, Mark Hofer, an attorney with Brown Rudnick Freed and Gesmer in Boston, will join the company’s business development and marketing board.

Maral will join GenOdyssee, of Les Ulis, France, after six years as director of clinical and scientific affairs at Chiron Biopharmaceuticals Europe, where he managed the clinical and preclinical development of several pharmaceutical products. Prior to Chiron, Maral served as medical director at Amgen France.

Hofer most recently oversaw intellectual property, public offerings, venture capital, entrepreneurial companies, and mergers and acquisitions at Brown Rudnick Freed and Gesmer. He also served as senior vice president, general counsel, and chief patent counsel at Genzyme in Cambridge, Mass.

GenOdyssee, founded in 1999, has specialized in identifying SNPs linked to disease using Denaturing High Performance Liquid Chromatography (DHPLC) and capillary sequencing, and studying the proteins encoded by those SNPs for use as possible therapeutics.

“These two distinguished individuals will be instrumental in helping us further our goal of developing drugs by applying an integrated approach to genetic variability,” Jean-Louis Escary, the company’s founder, president and chief scientific officer, said in a statement.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.